Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
49M
-
Shares change
-
-2.33M
-
Total reported value, excl. options
-
$76.5M
-
Value change
-
-$3.68M
-
Put/Call ratio
-
0.17
-
Number of buys
-
36
-
Number of sells
-
-37
-
Price
-
$1.56
Significant Holders of Xeris Biopharma Holdings, Inc. - COM (XERS) as of Q3 2022
111 filings reported holding XERS - Xeris Biopharma Holdings, Inc. - COM as of Q3 2022.
Xeris Biopharma Holdings, Inc. - COM (XERS) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49M shares
.
Largest 10 shareholders include Stonepine Capital Management, LLC (12.9M shares), VANGUARD GROUP INC (6.51M shares), CAXTON CORP (6.04M shares), NEA Management Company, LLC (3.25M shares), ARMISTICE CAPITAL, LLC (2.5M shares), GEODE CAPITAL MANAGEMENT, LLC (2.35M shares), STATE STREET CORP (2.17M shares), Invesco Ltd. (2.11M shares), NORTHERN TRUST CORP (1.09M shares), and Redmile Group, LLC (1.05M shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.